Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian investment firm Lodge Partners has initiated coverage of Genetic Technologies (GTG) with a Buy rating and 12-month price target of A$.57 ($.62), citing its BrevaGen breast cancer test and its IP portfolio as potential growth drivers.

The bank began its coverage nearly a month ago, and GTG made the report available on its website today.

Lodge also had a 2011 revenue estimate on GTG of A$21.5 million ($23.5 million) and EPS of A$.002.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.